- Molecular NameZalcitabine
- SynonymDDC; DDCYD; Dideoxycytidine
- Weight211.221
- Drugbank_IDDB00943
- ACS_NO7481-89-2
- Show 3D model
- LogP (experiment)-1.3
- LogP (predicted, AB/LogP v2.0)-1.11
- pkaN/A
- LogD (pH=7, predicted)-1.11
- Solubility (experiment)76.7 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.02
- LogSw (predicted, AB/LogsW2.0)50.22
- Sw (mg/ml) (predicted, ACD/Labs)20.15
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds2
- TPSA88.15
- StatusFDA approved
- AdministrationN/A
- PharmacologyA nucleoside analog reverse transcriptase inhibitor (NARTI)
- Absorption_value85.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability88.0
- Protein binding4.0
- Volume of distribution (VD)Adults: 0.54 L/kg; children: 9.3 L/m3.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half lifeAdults: 1 to 3 h; children: 0.8 h. Prolonged in patients with renal impairment, up to 8.5 h (with creatinine clearance < 55 mL/min).
- ExcretionRenal (circa 80%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAcute overdose: Inadvertent pediatric overdoses have occurred with doses up to 1.5 mg/kg zalcitabine. Chronic overdose: in an initial dose-finding study in which zalcitabine was administered at doses 25 times (0.25 mg/kg every 8 hours) the currently recommended dose, one patient discontinued zalcitabine after 1???? weeks of treatment subsequent to the development of a rash and fever.
- LD50 (rat)N/A
- LD50 (mouse)N/A